By

, ETMarkets.comLast Updated: Aug 18, 2026, 12:26:00 PM IST

Synopsis

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Shares of Biocon rose 2% to Rs 420.25 on the BSE on Tuesday, after the company’s subsidiary in the United States received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek 90 mg/ml single-dose prefilled autoinjector.

According to a regulatory filing by the company on the BSE, the Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.

“This supplemental approval enhances Biocon’s comprehensive portfolio of immunology products in the United States and reaffirms the company’s commitment to improving access to affordable medicines for patients around the world,” the company said, as per the regulatory filing.

Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients who are six years of age and older, and moderate to severely active Crohn’s disease and ulcerative colitis in adults, thereby treating a range of debilitating autoimmune conditions that affect tens of thousands of Americans.

Biocon Q1 Results

The company reported a net profit of Rs 141 crore in the June quarter of FY27. It reported a 10% year-on-year increase in consolidated operating revenue to Rs 4,336 crore, driven by strong growth in the Biopharma business. Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.

Consolidated EBITDA stood at Rs 902 crore, with a margin of 21%, supported by improved profitability in the Biopharma business, which helped offset continued challenges in the Services business.

Biocon Share Price

Shares of Biocon have gained nearly 3% in the last three months. However, the shares have slipped over 7% over the last six months.

The shares of the drugmaker have declined over 9% in 2026 so far. In the longer term, Biocon shares have fallen over 4% over one year, but have delivered 19% returns over three years and 39% returns over five years.

...moreless

...moreless